{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Constitutional+Mismatch+Repair+Deficiency+Syndrome&page=2",
    "query": {
      "condition": "Constitutional Mismatch Repair Deficiency Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Constitutional+Mismatch+Repair+Deficiency+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:32:20.881Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04439214",
      "title": "Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2016-05-31",
      "completion_date": "2020-05-17",
      "has_results": true,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439214"
    },
    {
      "nct_id": "NCT06708429",
      "title": "Lynch Syndrome X-Talk of Enteral Mucosa With Immune System",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lynch Syndrome",
        "Lynch Syndrome I",
        "Lynch Syndrome II",
        "Lynch Syndrome I (Site-specific Colonic Cancer)",
        "HNPCC",
        "HNPCC Gene Mutation",
        "Hereditary Cancer Syndrome",
        "Hereditary Cancer",
        "MLH1 Gene Mutation",
        "MLH1 Gene Deletion+Duplication",
        "MLH1 Loss of Expression",
        "MLH1 Gene Inactivation",
        "MSH2 Gene Mutation",
        "MSH2 Gene Deletion+Duplication",
        "MSH2 Loss of Expression",
        "MSH2 Gene Inactivation",
        "MSH6 Gene Mutation",
        "MSH6 Loss of Expression",
        "MSH6 Gene Inactivation",
        "PMS2 Gene Mutation",
        "PMS2 Gene Inactivation",
        "PMS2 Loss of Expression"
      ],
      "interventions": [
        {
          "name": "LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "San Raffaele University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-06-01",
      "completion_date": "2034-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 1,
      "location_summary": "Monrovia, California",
      "locations": [
        {
          "city": "Monrovia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708429"
    },
    {
      "nct_id": "NCT03935893",
      "title": "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Sarcoma",
        "Mesothelioma",
        "Neuroendocrine Tumors",
        "Squamous Cell Cancer",
        "Merkel Cell Carcinoma",
        "Mismatch Repair Deficiency",
        "Microsatellite Instability"
      ],
      "interventions": [
        {
          "name": "Tumor Infiltrating Lymphocytes (TIL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine + Cyclophosphamide combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Udai Kammula",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 240,
      "start_date": "2019-12-03",
      "completion_date": "2038-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-07-10",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03935893"
    },
    {
      "nct_id": "NCT05838768",
      "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers"
      ],
      "interventions": [
        {
          "name": "HRO761",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 123,
      "start_date": "2023-06-27",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05838768"
    },
    {
      "nct_id": "NCT03050268",
      "title": "Familial Investigations of Childhood Cancer Predisposition",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Leukemia",
        "Adenomatous Polyposis",
        "Adrenocortical Carcinoma",
        "AML",
        "BAP1 Tumor Predisposition Syndrome",
        "Carney Complex",
        "Choroid Plexus Carcinoma",
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Diamond-Blackfan Anemia",
        "DICER1 Syndrome",
        "Dyskeratosis Congenita",
        "Emberger Syndrome",
        "Familial Acute Myeloid Leukemia",
        "Familial Adenomatous Polyposis",
        "Fanconi Anemia",
        "Familial Cancer",
        "Familial Wilms Tumor",
        "Familial Neuroblastoma",
        "GIST",
        "Hereditary Breast and Ovarian Cancer",
        "Hereditary Paraganglioma-Pheochromocytoma Syndrome",
        "Hodgkin Lymphoma",
        "Juvenile Polyposis",
        "Li-Fraumeni Syndrome",
        "Lynch Syndrome",
        "MDS",
        "Melanoma Syndrome",
        "Multiple Endocrine Neoplasia Type 1",
        "Multiple Endocrine Neoplasia Type 2",
        "Neuroblastoma",
        "Neurofibromatosis Type 1",
        "Neurofibromatosis Type II",
        "Nevoid Basal Cell Carcinoma Syndrome",
        "Non Hodgkin Lymphoma",
        "Noonan Syndrome and Other Rasopathy",
        "Overgrowth Syndromes",
        "Pancreatic Cancer",
        "Peutz-Jeghers Syndrome",
        "Pheochromocytoma/Paraganglioma",
        "PTEN Hamartoma Tumor Syndrome",
        "Retinoblastoma",
        "Rhabdoid Tumor Predisposition Syndrome",
        "Rhabdomyosarcoma",
        "Rothmund-Thomson Syndrome",
        "Tuberous Sclerosis",
        "Von Hippel-Lindau Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1500,
      "start_date": "2017-04-06",
      "completion_date": "2037-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03050268"
    },
    {
      "nct_id": "NCT02359565",
      "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Lynch Syndrome",
        "Malignant Glioma",
        "Recurrent Brain Neoplasm",
        "Recurrent Childhood Ependymoma",
        "Recurrent Diffuse Intrinsic Pontine Glioma",
        "Recurrent Medulloblastoma",
        "Refractory Brain Neoplasm",
        "Refractory Diffuse Intrinsic Pontine Glioma",
        "Refractory Ependymoma",
        "Refractory Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Conventional Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Tensor Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Diffusion Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Contrast-enhanced MR Perfusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Spectroscopic Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 71,
      "start_date": "2015-06-03",
      "completion_date": "2027-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02359565"
    },
    {
      "nct_id": "NCT03460483",
      "title": "Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Carcinoma",
        "Lynch Syndrome",
        "Relatives"
      ],
      "interventions": [
        {
          "name": "Genetic Counseling",
          "type": "OTHER"
        },
        {
          "name": "Genetic Testing",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mutation Carrier Screening",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1001,
      "start_date": "2018-03-30",
      "completion_date": "2025-06-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 9,
      "location_summary": "Akron, Ohio • Canton, Ohio • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03460483"
    },
    {
      "nct_id": "NCT05129605",
      "title": "Prostate Cancer Genetic Risk Evaluation and Screening Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostatic Neoplasm",
        "Prostate Cancer",
        "BRCA2 Mutation",
        "BRCA1 Mutation",
        "ATM Gene Mutation",
        "MMR Mutation",
        "Lynch Syndrome",
        "Genetic Predisposition to Disease"
      ],
      "interventions": [
        {
          "name": "Prostate cancer screening",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "74 Years",
        "sex": "MALE",
        "summary": "35 Years to 74 Years · Male only"
      },
      "enrollment_count": 400,
      "start_date": "2020-02-12",
      "completion_date": "2040-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05129605"
    },
    {
      "nct_id": "NCT04500548",
      "title": "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Constitutional Mismatch Repair Deficiency Syndrome",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lynch Syndrome",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Recurrent Primary Central Nervous System Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Xeroderma Pigmentosum"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "12 Months to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-01-28",
      "completion_date": "2022-06-21",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04500548"
    },
    {
      "nct_id": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Melanoma",
        "Metastasis",
        "Pleural Mesothelioma",
        "Renal Cell Carcinoma",
        "MSI-High",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer",
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Renal Cell Cancer",
        "Kidney Cancer",
        "Skin Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
        "ALK Genomic Tumor Aberrations"
      ],
      "interventions": [
        {
          "name": "Alintegimod",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2024-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T22:32:20.881Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362369"
    }
  ]
}